OBP-002

OBP-002 is a first-in-class small molecule enzyme inhibitor being developed by OncoBone Therapeutics for the treatment of bone metastasizing malignancies. Currently in the lead optimization stage of preclinical development, the drug is being co-developed with the University of Bradford. OBP-002 is designed to target a specific enzyme involved in the progression of cancers that metastasize to the bone, though the identity of this enzyme has not been publicly disclosed. The company's strategy involves completing proof-of-concept and regulatory safety studies before seeking an out-licensing partner for clinical development, which is anticipated around 2029.